At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
ADAG Adagene
Trading 05-03 14:52:43 EDT
2.41
-0.07
-2.82%
High2.58
Low2.38
Vol6.83K
Open2.52
D1 Closing2.48
Amplitude8.06%
Mkt Cap106.42M
Tradable Cap25.04M
Total Shares44.16M
T/O16.92K
T/O Rate0.07%
Tradable Shares10.39M
P/B--
ROE--
EPS0.00
52wk High--
52wk Low--
P/E--
Dividend--
Div.Yield--
ROA--
Analysts Offer Insights on Healthcare Companies: eFFECTOR Therapeutics (EFTR), Adagene (ADAG) and Aquestive Therapeutics (AQST)
Adagene Announces Progress and Expansion of Clinical Collaboration Program for Masked, Anti-CTLA-4 SAFEbody® ADG126 (muzastotug) in Combination with KEYTRUDA® (pembrolizumab) to Demonstrate Further Efficacy in Patients with Metastatic Microsatellite-stable (MSS) Colorectal Cancer (CRC)
Adagene Inc. is a platform-driven, clinical-stage biopharmaceutical company committed to transforming the discovery and development of novel antibody-based cancer immunotherapies. Their platform is designed to generate therapeutic antibody candidates with unique functional epitopes and species cross-reactivity. These features enable their novel drug discovery strategy to advance from lead identification through vigorous preclinical modeling to biomarker-guided mono- and combination immunotherapy development in clinical settings. They have pioneered a dynamic interface design to harness the conformational diversity of antibodies, which enlarges epitope sampling of a given drug target for differentiated therapeutic antibody development. Their platform is designed to enable the rapid development of precision immunotherapy candidates, through the identification of predictive biomarkers for patient stratification and preselection.